États-Unis · Bourse & Finance · CNBC

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Publié par CNBC · États-Unis il y a 3 h

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

Lire l'article complet sur CNBC Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.cnbc.com)

À lire aussi

MetaMask exits Lido validators as it investigates security incident

Business Insider

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.